Cost Effectiveness of Riluzole in Amyotrophic Lateral Sclerosis
暂无分享,去创建一个
Andrea Messori | Sabrina Trippoli | G. Zaccara | A. Messori | S. Trippoli | Gaetano Zaccara | Paola Becagli | P. Becagli
[1] R. Gelber,et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. , 1996, Journal of the National Cancer Institute.
[2] S. Durrleman,et al. A confirmatory dose-ranging study of riluzole in ALS , 1996, Neurology.
[3] P. Leigh,et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.
[4] A. Messori,et al. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. , 1997, European journal of cancer.
[5] A. Messori,et al. Pharmacoeconomic profile of paclitaxel as a first‐line treatment for patients with advanced ovarian carcinoma: A lifetime cost‐effectiveness analysis , 1996, Cancer.
[6] D. Coyle. Statistical analysis in pharmacoeconomic studies. A review of current issues and standards. , 1996, PharmacoEconomics.
[7] B. Mcfarland,et al. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. , 1998, The New England journal of medicine.
[8] A. Messori,et al. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin’s lymphoma , 1997, Bone Marrow Transplantation.
[9] F. Cavalli,et al. Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer , 1991 .
[10] B. F. Cole,et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival , 1996, The Lancet.
[11] P. Sojka,et al. Effects of riluzole on symptom progression in amyotrophic lateral sclerosis , 1997, The Lancet.
[12] L. Rowland. Riluzole for the treatment of amyotrophic lateral sclerosis--too soon to tell? , 1994, The New England journal of medicine.
[13] J. Kirkwood,et al. Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity. , 1997, European journal of cancer.
[14] J. Sacristán,et al. Use of Confidence Intervals and Sample Size Calculations in Health Economic Studies , 1995, The Annals of pharmacotherapy.
[15] F. Locatelli,et al. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia , 1999, Bone Marrow Transplantation.
[16] Erry,et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.
[17] A. Messori. Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data. , 1997, Computer methods and programs in biomedicine.
[18] A. Messori,et al. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer , 1996, European Journal of Clinical Pharmacology.
[19] V. Meininger,et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.
[20] G. Ginsberg,et al. Cost-Benefit Analysis of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis , 1997, PharmacoEconomics.
[21] R. Sufit,et al. Clinical trials of riluzole in patients with ALS , 1996, Neurology.
[22] A. Messori,et al. Second bone marrow transplantation in non-Hodgkin's lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] L. Rowland. Assisted suicide and alternatives in amyotrophic lateral sclerosis. , 1998, The New England journal of medicine.
[24] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine , 1997 .
[25] Jacobson Mw. Cost effectiveness of coronary bypass surgery versus angioplasty. , 1997 .
[26] A. Messori. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] P. Benfield,et al. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. , 1996, Drugs.